Cytek Biosciences Analyst Ratings
Cytek Biosciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/19/2023 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 05/11/2023 | 44.44% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 05/10/2023 | 33.33% | Goldman Sachs | $14 → $12 | Maintains | Buy |
| 03/07/2023 | 66.67% | Piper Sandler | $18 → $15 | Maintains | Overweight |
| 03/02/2023 | 55.56% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 03/02/2023 | 55.56% | Goldman Sachs | $16 → $14 | Maintains | Buy |
| 08/18/2022 | 77.78% | Piper Sandler | $12 → $16 | Maintains | Overweight |
| 08/12/2022 | 66.67% | Morgan Stanley | $11 → $15 | Maintains | Equal-Weight |
| 08/11/2022 | 88.89% | Goldman Sachs | $15 → $17 | Maintains | Buy |
| 07/14/2022 | 66.67% | Goldman Sachs | $12 → $15 | Maintains | Buy |
| 05/16/2022 | 33.33% | Piper Sandler | $17 → $12 | Maintains | Overweight |
| 05/13/2022 | 22.22% | Morgan Stanley | $18 → $11 | Maintains | Equal-Weight |
| 05/12/2022 | 33.33% | Goldman Sachs | $14 → $12 | Maintains | Buy |
| 04/13/2022 | 55.56% | Goldman Sachs | $28 → $14 | Maintains | Buy |
| 02/15/2022 | 100% | Morgan Stanley | $27 → $18 | Maintains | Equal-Weight |
| 08/17/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/17/2021 | 188.89% | Morgan Stanley | → $26 | Initiates Coverage On | → Equal-Weight |
| 08/17/2021 | 211.11% | Goldman Sachs | → $28 | Initiates Coverage On | → Buy |
| 08/17/2021 | 211.11% | Piper Sandler | → $28 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 07/19/2023 | - | 雷蒙德·詹姆斯 | 开始承保 | →市场表现 | |
| 2023年05月11日 | 44.44% | 摩根士丹利 | $14→$13 | 维护 | 等重 |
| 2023年05月10日 | 33.33% | 高盛 | $14→$12 | 维护 | 买 |
| 03/07/2023 | 66.67% | 派珀·桑德勒 | $18→$15 | 维护 | 超重 |
| 03/02/2023 | 55.56% | 摩根士丹利 | $15→$14 | 维护 | 等重 |
| 03/02/2023 | 55.56% | 高盛 | $16→$14 | 维护 | 买 |
| 2022/08/18 | 77.78% | 派珀·桑德勒 | $12→$16 | 维护 | 超重 |
| 2022年08月12日 | 66.67% | 摩根士丹利 | $11→$15 | 维护 | 等重 |
| 2022年08月11日 | 88.89% | 高盛 | $15→$17 | 维护 | 买 |
| 07/14/2022 | 66.67% | 高盛 | $12→$15 | 维护 | 买 |
| 05/16/2022 | 33.33% | 派珀·桑德勒 | $17→$12 | 维护 | 超重 |
| 2022年05月13日 | 22.22% | 摩根士丹利 | $18→$11 | 维护 | 等重 |
| 2022年05月12日 | 33.33% | 高盛 | $14→$12 | 维护 | 买 |
| 04/13/2022 | 55.56% | 高盛 | $28→$14 | 维护 | 买 |
| 02/15/2022 | 100% | 摩根士丹利 | $27→$18 | 维护 | 等重 |
| 2021/08/17 | - | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 2021/08/17 | 188.89% | 摩根士丹利 | →$26 | 开始承保 | →等重 |
| 2021/08/17 | 211.11% | 高盛 | →$28 | 开始承保 | →购买 |
| 2021/08/17 | 211.11% | 派珀·桑德勒 | →$28 | 开始承保 | →超重 |
What is the target price for Cytek Biosciences (CTKB)?
赛特克生物科学公司(CTKB)的目标价格是多少？
The latest price target for Cytek Biosciences (NASDAQ: CTKB) was reported by Raymond James on July 19, 2023. The analyst firm set a price target for $0.00 expecting CTKB to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
雷蒙德·詹姆斯于2023年7月19日报道了赛特克生物科学公司(纳斯达克代码：CTKB)的最新目标价。这家分析公司将目标价定为0.00美元，预计CTKB将在12个月内下跌(跌幅可能为-100.00%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Cytek Biosciences (CTKB)?
Cytek Biosciences(CTKB)的最新分析师评级是什么？
The latest analyst rating for Cytek Biosciences (NASDAQ: CTKB) was provided by Raymond James, and Cytek Biosciences initiated their market perform rating.
最新的分析师对赛特克生物科学公司(纳斯达克代码：CTKB)的评级是由Raymond James提供的，赛特克生物科学公司启动了他们的市场表现评级。
When is the next analyst rating going to be posted or updated for Cytek Biosciences (CTKB)?
Cytek Biosciences(CTKB)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on July 19, 2023 so you should expect the next rating to be made available sometime around July 19, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Cytek Biosciences的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Cytek Biosciences的上一次评级是在2023年7月19日提交的，所以你应该预计下一次评级将在2024年7月19日左右的某个时候提供。
Is the Analyst Rating Cytek Biosciences (CTKB) correct?
分析师对Cytek Biosciences(CTKB)的评级正确吗？
While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a initiated with a price target of $0.00 to $0.00. The current price Cytek Biosciences (CTKB) is trading at is $9.00, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Cytek Biosciences(CTKB)评级是以0.00美元至0.00美元的目标价启动的。Cytek Biosciences(CTKB)目前的交易价格为9.00美元，超出了分析师的预测区间。